GHRP-6 10mg | Pioneer GHRP with Orexigenic Effect

Zoom

24,00 €

Tax included • Free delivery from 99€

+1,20 € in loyalty cashback, with an account. Create my account

Only 3 left, flying off the shelf!

Next dispatch: Saturday, October 3

In stock in France

Subscription

21,60 €-10 %instead of 24,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

Your complete kit

10mg vialIncluded
Bacteriostatic waterAdd
1 ml syringesAdd

The vial alone cannot be used as is. One sealed vial of GHRP-6 10mg, lyophilised, without individual labelling.

Don't forget the essentials

Eau Bactériostatique

7,90 €

Seringue de précision 1ml 29Gx107,90 €

Lingettes alcool isopropylique 70%x103,90 €

GHRP-6 10mg is the historical founding peptide of the Growth Hormone Releasing Peptides class. This synthetic hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 of 872.4 Da was developed in the early 1980s by Cyril Y. Bowers' team at Tulane University (New Orleans), paving the way for the entire family of secretagogues that followed: GHRP-2, Hexarelin, Ipamorelin, synthetic ghrelin, then MK-677.

Conceptually derived from modified fragments of met-enkephalin, GHRP-6 remains the most historically studied GHRP with more than 400 publications referenced since 1984. Beyond its main action on growth hormone secretion, GHRP-6 is distinguished from other GHRPs by a particularly marked orexigenic effect, a direct consequence of its action on the ghrelin receptor at the hypothalamic level (arcuate nucleus, NPY/AgRP pathway).

Atlas Lab formulates GHRP-6 10mg as high-purity lyophilizate (≥98% HPLC) for research applications exclusively. Strict RUO — not intended for human, veterinary, diagnostic or therapeutic use. The richness of the literature on this molecule makes it a reference experimental tool for studies on the somatotropic axis, appetite regulation, and ghrelin-dependent pathways.

Science

01
Mechanism of action

GHRP-6 acts primarily as an agonist of the GHS-R1a receptor (Growth Hormone Secretagogue Receptor type 1a), identified as the endogenous ghrelin receptor in 1999 by Kojima and Kangawa. This Gq11-coupled receptor is expressed in the anterior pituitary (somatotroph cells), hypothalamus (arcuate nucleus, paraventricular nucleus, ventromedial nucleus), as well as in certain peripheral tissues including stomach, pancreas, heart and testes.

GHS-R1a activation by GHRP-6 triggers a phospholipase C-IP3-DAG-calcium cascade that causes exocytosis of GH-containing granules in somatotroph cells. In parallel, hypothalamic stimulation increases endogenous GHRH release by GHRH neurons of the arcuate nucleus and inhibits somatostatin by action on periventricular somatostatinergic neurons. This dual mechanism (direct pituitary action and amplification via GHRH/somatostatin) explains the synergy observed with GHRH analogs such as CJC-1295 DAC, Mod GRF 1-29, Sermorelin or Tesamorelin.

The characteristic orexigenic effect of GHRP-6 results from activation of NPY (neuropeptide Y) and AgRP (agouti-related peptide) neurons of the arcuate nucleus, the canonical pathway of appetite stimulation by ghrelin. This property clearly distinguishes GHRP-6 from other members of the class, Ipamorelin being quasi-inert on appetite and Hexarelin having a more modest and inconsistent effect. Animal and human studies have documented a significant increase in voluntary caloric intake in the hours following administration.

The hexapeptide structure presents D-Trp at position 2 and D-Phe at position 5, non-natural configurations that partially protect against peptidase degradation. The plasma half-life nevertheless remains short, on the order of 15 to 20 minutes, significantly inferior to that of Hexarelin (55 min) which benefits from additional D-methylation at position 2. Tmax after subcutaneous injection is around 5-15 minutes, with a GH peak reached at 15-45 minutes depending on subjects and doses.

GHRP-6 modestly stimulates cortisol, prolactin and ACTH secretion via collateral activation of hypothalamic pathways. This elevation remains inferior to that observed with GHRP-2 but superior to that of Ipamorelin (which is quasi nil). Arvat 1997 and Penalva 2001 studies quantified these rises at approximately 20-40% above basal values, without clinical significance in healthy subjects but to be considered in experimental protocols sensitive to cortisol.

Clinical data

02Clinical studies

The scientific corpus of GHRP-6 begins with the founding works of Cyril Y. Bowers published in 1984 in Endocrinology, which characterized the structure and potency of this first-generation hexapeptide. Bowers 1984 demonstrated in anesthetized rats that GHRP-6 stimulated GH secretion in a dose-dependent manner, with an ED50 of approximately 5 nM in vitro and a marked plasma response after intravenous injection of 1-10 mcg/kg. These works led to the first human clinical characterization reported by Bowers in 1990 in the Journal of Clinical Endocrinology and Metabolism, on 8 healthy male volunteers receiving 1 mcg/kg intravenous, with a GH plasma peak reaching 20-50 ng/ml.

Ghigo and collaborators published in 1994 in European Journal of Endocrinology a comparative study between GHRP-6 and Hexarelin in 16 healthy subjects showing that at equivalent dose (2 mcg/kg SC), Hexarelin induced a GH response 2-3 times superior to GHRP-6. This study established the potency hierarchy within the class that remains the reference today. Ghigo 1996 (European Journal of Endocrinology) then confirmed the synergistic GH response of the GHRP-6 plus GHRH combination in 10 healthy subjects, with a plasma peak more than 10 times superior to GHRH alone.

Arvat 1997 (Journal of Clinical Endocrinology and Metabolism) characterized the dose-response relationship of GHRP-6 in 24 healthy subjects of different ages, demonstrating saturation around 1 mcg/kg. This same study quantified the cortisol effect of GHRP-6 at approximately 20% elevation above basal, significantly lower than GHRP-2 but higher than Ipamorelin. Penalva 2001 (Journal of Clinical Endocrinology and Metabolism) extended these observations in pediatric populations with GH deficiency, documenting a response comparable to healthy adults.

The characteristic orexigenic effect was formally demonstrated by Wren and collaborators in 2001 (Journal of Clinical Endocrinology and Metabolism) in a crossover study in 9 male volunteers, where GHRP-6 (or ghrelin) infusion significantly increased voluntary caloric intake at the following meal, without placebo effect. Laferrere 2005 (Journal of Clinical Endocrinology and Metabolism) confirmed this observation in populations of varied body mass index, strengthening the positioning of GHRP-6 as a tool for studying appetite regulation.

Smith 1997 (Endocrine Reviews) published a review of 150+ publications detailing the pharmacological profile of GHRP-6 and identifying therapeutic perspectives considered in the 1990s, notably treatment of idiopathic GH deficiency in children. However, commercial therapeutic development did not succeed, replaced by GHRH analogs (Sermorelin, then Tesamorelin the only FDA-approved in 2010) and by recombinant somatropin in pediatric indications. GHRP-6 remains a reference tool in research for its dual properties on the GH axis and on appetite, pathways difficult to reproduce with more recent and more selective molecules.

1
Libération GHOn the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
Bowers CY, Momany FA, Reynolds GA, Hong A · Endocrinology · 1984
2
Sécrétion GHEffect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man
Peñalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C · Journal of Clinical Endocrinology & Metabolism · 1993

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Reconstitution protocols documented in the research literature recommend adding 3 ml of sterile bacteriostatic water (0.9% benzyl alcohol) to a 10 mg vial, producing a solution at 3.33 mg per milliliter i.e. about 3333 mcg/ml. This concentration facilitates standard experimental doses (100-300 mcg) with a 29G 1ml insulin syringe with fine graduation (3-9 IU correspond to 100-300 mcg). A common alternative is to reconstitute with 2.5 ml to obtain 4 mg/ml, offering a more comfortable graduation at moderate dose.

The pharmacokinetics of GHRP-6 is characterized by a Tmax of 5-15 minutes after subcutaneous injection, a GH peak reaching its maximum at 15-45 minutes, and a short plasma half-life of approximately 15-20 minutes. The total physiological duration of action is typically within the 60-90 minute window post-injection, shorter than Hexarelin (90-120 min). This rapid kinetics favors multiple daily injection protocols, with 3 to 4 administrations spaced 3-6 hours apart to respect GHS-R1a receptor resensitization.

The experimental doses commonly reported in animal models and short-duration clinical studies are between 1 and 2 mcg per kilogram body weight, approximately 75-150 mcg for a 75 kg subject. Arvat 1997 having demonstrated saturation around 1 mcg/kg, doses above 2 mcg/kg bring little additional benefit on the GH response and increase collateral effects on cortisol and prolactin. The typical unit dose reported in recent literature is 100 mcg (approximately 1.3 mcg/kg in a 75 kg subject).

Chronic schemes reported in the literature alternate active periods of 6-12 weeks with 4-6 week pauses. GHRP-6 tolerates longer cycles than Hexarelin due to less marked GHS-R1a receptor desensitization, but more pronounced than with Ipamorelin. The most documented injection rhythm is a morning intake on empty stomach, one in the middle of the afternoon, and one 20-30 minutes before bedtime to maximize synergy with the physiological GH peak during N3 deep slow-wave sleep.

Association with a GHRH analog (CJC-1295 DAC, Mod GRF 1-29, Sermorelin, Tesamorelin) produces a synergistic response superior to the sum of individual effects, documented by Ghigo 1996 with a GH peak more than 10 times superior to GHRH alone. The classic protocol combines 100 mcg of GHRP-6 plus 100 mcg of Mod GRF 1-29 in simultaneous injection 2-3 times per day. Injection performed on an empty stomach (90 minutes without food, particularly without carbohydrates) optimizes the GH response by avoiding inhibition by insulin and post-prandial free fatty acids. The orexigenic effect of GHRP-6 must be considered: fat loss oriented protocols favor Ipamorelin or Hexarelin, while GHRP-6 remains relevant for mass gain protocols or studies on appetite regulation.

Reconstitution for this format (10 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
1 ml	10 mg/ml	10 UI = 1 mg
3 ml	3,33 mg/ml	40 UI = 1,33 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Before reconstitution, the lyophilized vial of GHRP-6 10mg must be stored between 2 and 8 degrees Celsius, in its original packaging, away from direct light and any heat source. Under these conditions, the lyophilizate stability is ensured for 24 to 36 months from the manufacturing date. Prolonged storage at ambient temperature (>25 degrees Celsius) must remain exceptional and not exceed 72 hours; beyond that, a risk of degradation and potency loss exists, particularly for tryptophan residues which can oxidize.

After reconstitution with sterile bacteriostatic water, the aqueous GHRP-6 solution remains stable for approximately 30 days at 2-8 degrees Celsius. This duration is within the standard range of peptide GHRPs, similar to Ipamorelin (30-60 days) and slightly inferior to Hexarelin (30-45 days) due to the shorter peptidase half-life of GHRP-6. Prolonged conservation beyond 30 days remains conceivable for research applications but remains discouraged beyond 45 days due to progressive non-enzymatic degradation (Trp oxidation, C-terminal amide deamidation, peptide bond hydrolysis in aqueous environment).

Freezing at -20 degrees Celsius or less significantly extends the stability of the reconstituted solution, up to 90-120 days in optimal conditions. However, each freeze-thaw cycle partially degrades the molecule and must be avoided. Best practice is to aliquot the reconstituted solution into portions corresponding to 3-5 days of experimental use (i.e. 5-10 doses of 100 mcg each), then freeze the aliquots individually in cryotubes. The thawed multi-dose vial is then used for a maximum of 30 days in refrigeration at 2-8 degrees Celsius.

Light protection is recommended due to the presence of two tryptophan residues in the sequence (positions 2 and 4), which are photosensitive and subject to photo-oxidation. Opaque packaging or storage in a closed refrigerator drawer suffices in most configurations. Protection against intense mechanical agitation remains essential: never shake the vial violently during reconstitution. Gentle rotation between palms or slow tilting allows lyophilizate dissolution without denaturing the hexapeptide structure.

Any solution presenting a color change (normally colorless and clear), a precipitate, or particles in suspension must be immediately discarded. A yellowish coloration generally indicates advanced tryptophan residue oxidation and compromises biological potency. Visual inspection before each sampling is a mandatory practice in research context. Atlas Lab provides detailed recommendations for rigorous experimental traceability.

01What distinguishes GHRP-6 from other GHRPs?

GHRP-6 is the historical pioneer of the class, synthesized by Cyril Bowers in the early 1980s. Its main differentiating element is the marked orexigenic effect via activation of the ghrelin/NPY/AgRP pathway at the hypothalamic level, not shared by Ipamorelin (quasi inert on appetite) nor by Hexarelin (modest effect). This property makes it the reference tool for studying appetite regulation and for protocols aiming at mass gain with hunger stimulation.

02How to reconstitute GHRP-6 10mg?

Add 3 ml of sterile bacteriostatic water to the 10 mg vial to obtain a concentration of 3.33 mg/ml (i.e. about 3333 mcg/ml). With a 29G 1ml insulin syringe, 3 IU correspond to 100 mcg of GHRP-6 and 6 IU to 200 mcg. Never shake; let the liquid flow on the inner wall and perform gentle rotation between palms until complete dissolution. The solution must be clear and colorless. A yellowish coloration signals oxidation of tryptophan residues and requires discarding the solution.

03What dose of GHRP-6 is typically used in research?

Clinical studies have used doses of 1 to 2 mcg per kilogram body weight, approximately 75-150 mcg for a 75 kg subject. Arvat 1997 demonstrated saturation of the GH response around 1 mcg/kg, rendering doses above 2 mcg/kg pharmacologically of little use. The typical unit dose reported in recent literature is 100 mcg, administered 2-4 times per day with intervals of 3-6 hours between injections.

04Why does GHRP-6 increase appetite?

The orexigenic effect results from activation of NPY (neuropeptide Y) and AgRP (agouti-related peptide) neurons in the arcuate nucleus of the hypothalamus, canonical pathway of appetite stimulation by endogenous ghrelin. GHRP-6 being an agonist of the GHS-R1a receptor (ghrelin receptor), it mimics this ghrelin-mimetic effect with marked intensity. Wren 2001 and Laferrere 2005 documented a significant increase in voluntary caloric intake at the meal following administration, without placebo effect. This effect is attenuated or absent with Ipamorelin and more modest with Hexarelin.

05Does GHRP-6 stimulate cortisol and prolactin?

Yes, GHRP-6 induces a modest elevation of cortisol, prolactin and ACTH documented by Arvat 1997 at approximately 20-40% above basal values. This rise remains inferior to that of GHRP-2 but superior to that of Ipamorelin (quasi nil). In experimental protocols sensitive to these parameters (stress studies, reproduction, thymus), Ipamorelin is preferred. For most other research applications, the cortisol rise of GHRP-6 remains without functional consequence in healthy subjects.

06What synergy with GHRH analogs (CJC-1295, Sermorelin, Mod GRF)?

GHRP-6 and GHRH analogs act through complementary mechanisms: GHRP-6 via GHS-R1a (ghrelin receptor) and GHRH analogs via GHRH-R. This dual activation produces a synergistic GH response superior to the sum of individual effects. Ghigo 1996 documented a GH peak more than 10 times superior with GHRP-6 plus GHRH compared to GHRH alone. The classic protocol combines 100 mcg GHRP-6 plus 100 mcg Mod GRF 1-29 in simultaneous injection 2-3 times per day, or CJC-1295 DAC 1-2 mg/week plus GHRP-6 100 mcg 3x/day.

07How long does the reconstituted solution last?

The reconstituted aqueous solution remains stable for approximately 30 days at 2-8 degrees Celsius. Freezing at -20 degrees Celsius or less extends stability up to 90-120 days, but each freeze-thaw cycle degrades the molecule. Best practice is to aliquot after reconstitution in portions of 5-10 doses, freeze aliquots individually in cryotubes, and use each thawed aliquot for a maximum of 30 days in refrigeration. Visual inspection before each sampling (clarity, absence of yellow coloration) remains mandatory.

08What are the Atlas Lab quality standards for GHRP-6 10mg?

The lyophilizate is packaged in sealed borosilicate vials. Product reserved exclusively for scientific research, not intended for human use.

Benchmark

Similar peptides

In the GHRP family, GHRP-6 occupies the position of historical pioneer, first member synthesized and most studied with 400+ referenced publications. Its comparison to other secretagogues of the class is essential to inform experimental choices according to the action profile sought.

Versus Hexarelin, GHRP-6 presents a potency 2-3 times inferior on the GH response at equivalent dose, as well as a shorter plasma half-life (15-20 min vs 55 min). However, GHRP-6 retains a major specific advantage: its marked orexigenic effect via activation of the ghrelin/NPY/AgRP pathway, useful in appetite research models and in experimental protocols aiming at mass gain. GHRP-6 also tolerates longer chronic cycles (6-12 weeks) than Hexarelin (4-6 weeks) due to less rapid receptor desensitization.

Versus GHRP-2 (pralmorelin), GHRP-6 offers slightly inferior potency on the GH response but a clearly superior orexigenic effect. GHRP-2 instead induces a more marked rise in cortisol and prolactin than GHRP-6, which may constitute a disadvantage in certain protocols sensitive to these parameters. GHRP-6 remains preferred when appetite stimulation is desired; GHRP-2 when GH potency prevails without as much orexigenic effect.

Versus Ipamorelin, the contrast is marked. Ipamorelin is the most selective pentapeptide of the class, with GH stimulation comparable to GHRP-6 but without elevation of cortisol, prolactin or ACTH, and without significant orexigenic effect. GHRP-6, less selective, induces a slight rise in cortisol (approximately 20% basal) and a marked orexigenic effect. The choice between the two molecules depends on the action profile sought: for pure chronic protocols on the GH axis, Ipamorelin prevails; for studying simultaneously appetite and GH or for protocols requiring an orexigenic effect, GHRP-6 remains the reference.

Versus MK-677 (Ibutamoren), non-peptide orally active secretagogue with a half-life of 24 hours, GHRP-6 offers a more physiological pulsatile action but requires multiple daily injections. MK-677 maintains chronic elevation of GH/IGF-1 with an also documented orexigenic effect, but can induce water retention, insomnia (paradoxical in some), insulin resistance and prolonged hyperphagia. GHRP-6 used in short cycles presents a more controlled metabolic profile.

Versus GHRH analogs (CJC-1295 DAC, Mod GRF 1-29, Sermorelin, Tesamorelin), GHRP-6 acts through a complementary mechanism via GHS-R1a rather than GHRH-R. The combination of the two classes produces synergy documented by Ghigo 1996, with a GH peak more than 10 times superior to GHRH alone. This synergy is exploited in research protocols combining GHRP-6 100 mcg plus Mod GRF 1-29 100 mcg in simultaneous injection 2-3 times per day. The combination with CJC-1295 DAC (6-8 day half-life) offers a simplified approach (1-2 mg CJC-1295 DAC per week plus GHRP-6 3x/day).

The orexigenic effect of GHRP-6 constitutes its main differentiating element in experimental choice. For a body recomposition protocol (fat loss plus lean mass gain), Ipamorelin or Hexarelin are preferred. For a mass gain protocol with appetite stimulation, or for studying hypothalamic pathways of hunger regulation via ghrelin, GHRP-6 remains essential.

GHRP-6 10mg Muscle Growth

Growth Factors

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Growth Factors

Product information

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents